Study details
Enrolling now
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics, Inc.
NCT IDNCT07012395ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
645
Study length
about 2.8 years
Ages
18+
Locations
21 sites in CA, CO, FL +10
What this study is about
Researchers are testing a new treatment, SPY001, SPY002, or SPY003, alone or in combination with a placebo, for people with moderate to severe ulcerative colitis. The trial will last 1039 days and involve approximately 645 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take SPY001
- 3.Take SPY002
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Gastroenterology